Copyright
©The Author(s) 2022.
World J Clin Oncol. May 24, 2022; 13(5): 352-365
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.352
Published online May 24, 2022. doi: 10.5306/wjco.v13.i5.352
Hazard ratio | Standard error | P value | ||
Age group (%) | 20-59 | 0.931 | 0.327 | 0.83 |
≥ 60 | 2.554 | 0.557 | 0.09 | |
Sex (%) | Male | 1.169 | 0.288 | 0.59 |
Race (%) | API | 0.624 | 0.581 | 0.42 |
Black | 2.296 | 0.461 | 0.07 | |
Hispanic | 0.9 | 0.368 | 0.78 | |
Income (%) | $55000-70000 | 1.044 | 0.368 | 0.91 |
> $70000 | 0.644 | 0.345 | 0.2 | |
Sugery | Surgery | 1.465 | 0.472 | 0.42 |
Population (%) | ≥ 1 million | 1.209 | 0.287 | 0.51 |
Size (%) | ≥ 100 mm | 1.104 | 0.44 | 0.82 |
51-100 mm | 1.233 | 0.426 | 0.62 | |
Unknown | 3.196 | 0.646 | 0.07 | |
Lymph nodes (%) | N1 | 1.503 | 0.39 | 0.3 |
Nx | 0.107 | 0.993 | 0.02 | |
Metastasis status (%) | M1 | 0.301 | 0.782 | 0.13 |
Mx | 7.503 | 1.366 | 0.14 |
- Citation: Sempokuya T, Forlemu A, Azawi M, Silangcruz K, Khoury N, Ma J, Wong LL. Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study. World J Clin Oncol 2022; 13(5): 352-365
- URL: https://www.wjgnet.com/2218-4333/full/v13/i5/352.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i5.352